"FDA Committee Defies Agency Scientists, Approves Compounded Peptides for Pharmacy Use" In a surprising move, the Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) has voted to allow compounding pharmacies to produce certain peptides, despite concerns raised by agency scientists. The peptides in question, including BPC-157, KPV, TB-500, and MOTS-C, have been touted for their potential health benefits, but the FDA's own scientists have expressed skepticism about their effectiveness. At a meeting on Thursday, the committee heard from agency staffers and members of the public, who weighed in on the safety and benefits of these peptides. The decision to add these substances to the list of allowed compounding pharmacy products marks a significant departure from the FDA's usual caution, and could have far-reaching implications for the pharmaceutical industry.
The Food and Drug Administration's (FDA) committee on compounded drugs on Thursday broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make, despite concerns being raised over the lack of demonstrated benefits. The FDA's Pharmacy Compounding Advisory Committee (PCAC) heard public comments and saw presentation by agency staffers concerning the peptides BPC-157, KPV, TB-500 and MOTS-C. These peptides...
